Piramal Critical Care Inc said that a patent litigation between it and Baxter Healthcare Corporation related to the generically similar version of Baxter’s inhaled anesthetic agent Suprane (Desflurane) has been dismissed by the United States District Court for the District of Delaware, following a settlement between the parties.
Suprane is Baxter’s product of Desflurane, an anesthetic agent typically used in hospital settings. And Piramal Critical Care Inc is a subsidiary of Piramal Healthcare Limited.
As per the settlement, Piramal has obtained a license to the Baxter patent at issue in the lawsuit, following which the parties agree that Piramal may launch its generic Desflurane product in the United States as of January 1, 2014, subject to US regulatory approval, a Piramal note said.
Piramal has agreed not to make, use, sell or offer for sale in the United States, or import into the United States, this product prior to January 1, 2014, it added.
However, Piramal has taken a license under the patent pursuant to which the parties agree that Piramal may manufacture its generic Desflurane product in the United States as of April 24, 2012 solely for sale outside the United States in markets where it has obtained or will obtain regulatory registrations. Other terms of the settlement agreement were not disclosed.